Impact of blood collection devices on clinical chemistry assays

被引：146

作者：

Bowen, Raffick A. R. ^{[1
]}

Hortin, Glen L. ^{[2
]}

Csako, Gyorgy ^{[3
]}

Otanez, Oscar H. ^{[1
]}

Remaley, Alan T. ^{[3
]}

机构：

[1] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA

[2] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32608 USA

[3] NIH, Dept Lab Med, Bethesda, MD 20892 USA

来源：

CLINICAL BIOCHEMISTRY | 2010年 / 43卷 / 1-2期

关键词：

Blood collection devices; Surfactant; Interference; Clinical assay; Tube; Clinical chemistry; Preanalytical; Phlebotomy; SERUM SEPARATOR TUBES; COAGULATION ACTIVATION MARKERS; IONIZED CALCIUM MEASUREMENTS; GEL BARRIER FORMATION; CENTRAL VENOUS LINES; SAMPLE STORAGE TIME; MACRO SOLID-PHASES; GLASS SYRINGES; WHOLE-BLOOD; MASS-SPECTROMETRY;

D O I：

10.1016/j.clinbiochem.2009.10.001

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Blood collection devices interact with blood to alter blood composition, serum, or plasma fractions and in some cases adversely affect laboratory tests. Vascular access devices may release coating substances and exert shear forces that lyse cells. Blood-dissolving tube additives can affect blood constituent stability and analytical systems. Blood tube stoppers, stopper lubricants, tube walls, surfactants, clot activators, and separator gels may add materials, adsorb blood components, or interact with protein and cellular components. Thus, collection devices can be a major source of preanalytical error in laboratory testing. Device manufacturers, laboratory test vendors, and clinical laboratory personnel must understand these interactions as potential sources of error during preanalytical laboratory testing. Although the effects of endogenous blood substances have received attention, the effects of exogenous Substances on assay results have not been well described. This review will identify sources of exogenous substances in blood specimens and propose methods to minimize their impact on clinical chemistry assays. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

引用

页码：4 / 25

页数：22

共 318 条

[1]

ALI K, 1982, Patent No. 4420517

[2] Evaluation of polyethylene terephthalate for ABO and Rh typing and alloantibody screening [J].

Anderson, DR ;

Wiseman, J ;

MacLeod, J ;

Burton, E ;

Zayed, E .

TRANSFUSION, 2000, 40 (06) :669-672

[3]

[Anonymous], IMPORTANT SAFETY INF

[4]

Anraku H SY, 1989, U.S. Patent, Patent No. [8,565,334, 8565334]

[5] Influence of blood specimen collection method on various preanalytical sample quality indicators [J].

Ashavaid T.F. ;

Dandekar S.P. ;

Keny B. ;

Bhambhwani V.R. .

Indian Journal of Clinical Biochemistry, 2008, 23 (2) :144-149

[6]

ASTLES R, 1994, CLIN CHEM, V40, P1327

[7]

AUGELLO FA, 2000, Patent No. 6602718

[8] Effects of storage time and exogenous protease inhibitors on plasma protein levels [J].

Ayache, Saleh ;

Panelli, Monica ;

Marincola, Francesco M. ;

Stroncek, David F. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (02) :174-184

[9]

BABSON AL, 1979, Patent No. 4152269

[10]

BACH PR, 1991, PEDIAT LAB MED, V9, P5

← 1 2 3 4 5 6 7 8 9 10 →